[CLSN] Celsion Corporation


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 0.36 Change: 0.01 (2.77%)
Ext. hours: Change: 0 (0%)

chart CLSN

Refresh chart

Strongest Trends Summary For CLSN

CLSN is in the medium-term down -20% below S&P in 1 month and down -32% below S&P in 8 months. In the long-term down -42% below S&P in 1 year and down -99% below S&P in 11 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Celsion Corporation, an oncology drug development company, focuses on the development and commercialization of chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company?s lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; under Phase II clinical trials for recurrent chest wall breast cancer; and in phase II clinical trials for colorectal liver metastasis. It has a development, product supply, and commercialization agreement with Yakult Honsha Co. Ltd. for ThermoDox; and a commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. for the production of ThermoDox in mainland China, Hong Kong, and Macau. The company was founded in 1982 and is based in Lawrenceville, New Jersey.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 0% Sales Growth - Q/Q0% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-45.29% ROE-101.39% ROI-58.71%
Current Ratio2.98 Quick Ratio Long Term Debt/Equity0.25 Debt Ratio0.39
Gross Margin Operating Margin-5185.2% Net Profit Margin-5415.2% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-880 K Cash From Investing Activities1.74 M Cash From Operating Activities-5.94 M Gross Profit
Net Profit-7.01 M Operating Profit-6.59 M Total Assets59.78 M Total Current Assets30.67 M
Total Current Liabilities10.29 M Total Debt8.94 M Total Liabilities33.08 M Total Revenue120 K
Technical Data
High 52 week2.96 Low 52 week1.36 Last close1.68 Last change-0.59%
RSI43.18 Average true range0.09 Beta0.48 Volume760.88 K
Simple moving average 20 days-3.84% Simple moving average 50 days-5.78% Simple moving average 200 days-16.48%
Performance Data
Performance Week-3.45% Performance Month-5.08% Performance Quart-22.22% Performance Half-20.38%
Performance Year-38.69% Performance Year-to-date19.15% Volatility daily2.3% Volatility weekly5.14%
Volatility monthly10.54% Volatility yearly36.52% Relative Volume626.49% Average Volume103.49 K
New High New Low


2019-10-04 07:52:22 | Is Celsion NASDAQ:CLSN Using Debt In A Risky Way?

2019-10-01 08:00:00 | Celsion Strengthens Its 2019 Balance Sheet with the Approval of Its Application to Sell Net Operating Losses for $2.1 Million in Non-Dilutive Funding

2019-09-30 14:30:00 | Celsion to Present at the Chardan 3rd Annual Genetic Medicines Conference

2019-09-23 08:00:00 | Celsion Co-sponsors Hepatocellular Carcinoma Symposium at the International Liver Cancer Association ILCA Annual Conference

2019-09-04 06:32:17 | Market Sentiment Around Loss-Making Celsion Corporation NASDAQ:CLSN

2019-08-27 08:00:00 | Celsion Announces Publication of Findings from Single-Site Study in China of ThermoDox® Plus RFA in the Journal of Cancer Research and Therapeutics

2019-08-19 14:53:39 | Edited Transcript of CLSN earnings conference call or presentation 15-Aug-19 3:00pm GMT

2019-08-14 16:30:00 | Celsion Corporation Reports Second Quarter 2019 Financial Results and Provides Business Update

2019-08-13 08:01:00 | Celsion Announces Publication of Results of National Institutes of Health NIH Analysis of ThermoDox® in Journal of Vascular and Interventional Radiology

2019-08-09 08:30:00 | Celsion's GEN-1 Immunotherapy Highlighted in Oppenheimer's Expert Call on Ovarian Cancer Treatment Landscape and Emerging Opportunities

2019-08-08 08:30:00 | Celsion Corporation to Hold Second Quarter 2019 Financial Results Conference Call on Thursday, August 15, 2019

2019-08-06 10:30:02 | Will Celsion CLSN Report Negative Q2 Earnings? What You Should Know

2019-08-05 09:00:00 | Celsion Announces Data Lock for First Interim Analysis in OPTIMA Phase III Study of ThermoDox® in Primary Liver Cancer

2019-08-05 07:31:10 | Before You Buy Celsion Corporation NASDAQ:CLSN, Consider Its Volatility

2019-06-20 08:30:00 | Celsion Announces IRB Approval to Begin a Clinical Study of ThermoDox® Plus High Intensity Focused Ultrasound in Breast Cancer Patients at University Medical Center Utrecht in the Netherlands

2019-05-15 18:35:46 | Edited Transcript of CLSN earnings conference call or presentation 15-May-19 3:00pm GMT

2019-05-15 09:00:00 | Celsion Corp. to Host Earnings Call

2019-05-15 08:00:00 | Celsion Corporation Reports First Quarter 2019 Financial Results and Provides Business Update

2019-05-13 09:30:01 | Is Celsion CLSN Stock Outpacing Its Medical Peers This Year?

2019-05-13 08:44:12 | Blueprint Medicines BPMC Q1 Earnings & Sales Lag Estimates

2019-05-10 10:11:02 | Spectrum Pharma SPPI Q1 Earnings Lag Estimates, Revenues Nil

2019-05-10 10:00:02 | Puma Biotech PBYI Q1 Earnings Top, Nerlynx Disappoints

2019-05-09 15:03:07 | IVERIC bio's ISEE Q1 Loss Narrows, Gene Therapy in Focus

2019-05-09 11:05:03 | Sarepta SRPT Q1 Earnings Top Estimates, Exondys 51 Sales Up

2019-05-09 09:03:01 | Arena Pharmaceuticals' ARNA Loss Widens in Q1 But Stock Up

2019-05-08 17:00:00 | Celsion Corporation to Hold First Quarter 2019 Financial Results Conference Call on Wednesday, May 15, 2019

2019-05-08 10:30:02 | Will Celsion CLSN Report Negative Earnings Next Week? What You Should Know

2019-05-07 17:50:09 | Celsion CLSN Dips More Than Broader Markets: What You Should Know

2019-05-01 17:50:09 | Celsion CLSN Flat As Market Sinks: What You Should Know

2019-04-26 11:11:03 | Medicines Company MDCO Q1 Loss Narrows, Inclisiran in Focus

2019-04-26 10:59:02 | AstraZeneca's AZN Q1 Earnings Beat, New Drugs Drive Sales

2019-04-26 09:30:01 | Is Celsion CLSN Outperforming Other Medical Stocks This Year?

2019-04-25 09:31:01 | Alexion ALXN Q1 Earnings Beat Estimates, Guidance Raised

2019-04-17 08:14:12 | Ultragenyx's RARE UX007 Gets Fast Track Status by FDA

2019-04-17 08:00:00 | Celsion Corporation Announces Issuance of New Patent for ThermoDox®

2019-04-16 19:26:11 | ProQR Initiates Dosing in Phase II/III Eye Disorder Study

2019-04-12 08:30:00 | Celsion Corporation to Participate in Two Investor Conferences in May 2019

2019-04-12 08:00:00 | Celsion Corporation to Hold First Quarter 2019 Financial Results Conference Call on Wednesday, May 15, 2019

2019-04-11 12:34:00 | SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Celsion Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors

2019-04-03 09:00:01 | Celsion CLSN Moves to Strong Buy: Rationale Behind the Upgrade

2019-03-29 18:23:08 | Edited Transcript of CLSN earnings conference call or presentation 29-Mar-19 3:00pm GMT

2019-03-29 08:00:00 | Celsion Corporation Reports 2018 Financial Results

2019-03-22 08:30:00 | Celsion Corporation to Hold Year-End 2018 Financial Results Conference Call on Friday, March 29, 2019

2019-03-04 08:30:00 | Celsion Announces GEN-1 Data Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium

2019-02-21 16:30:00 | Celsion Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2019-02-01 07:30:00 | Consolidated Research: 2019 Summary Expectations for Southwest Airlines, Southern Copper, SEI Investments, Forward Air, Cincinnati Financial, and Celsion — Fundamental Analysis, Key Performance Indications

2019-01-24 11:30:00 | Celsion Corporation to Present at NobleConXV – Noble Capital Markets’ 15th Annual Investor Conference

2019-01-17 08:30:00 | Celsion Announces Publication of ThermoDox® Study Results in Radiology

2019-01-15 08:30:00 | Celsion Announces Presentation of GEN-1 Data at Upcoming ASCO-SITC Clinical Immuno-Oncology Symposium

2018-12-18 08:00:00 | Data Monitoring Committee DMC Completes Planned Safety and Data Review of Celsion’s Phase III OPTIMA Study of ThermoDox® for Treatment of Primary Liver Cancer